Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLK286 + Doxil in Platinum Refractory/Resistant Ovarian Cancer
NCT00052065Phase 2Completed
- Sponsor
- Telik, Inc.
- Start
- Feb 2003
- Primary completion
- Mar 2006
- Modality
- DNA Intercalators/Alkylators, Peptides, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of canfosfamide in ovarian cancer, sponsored by Telik, Inc.. Started Feb 2003; status: completed.
02
Drugs
canfosfamide
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00052065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00052065.